WHO releases revised recommendations for hormonal contraceptive use for women at high risk of HIV and women living with HIV
24 July 2014 – During the AIDS 2014 conference in Melbourne, the World Health Organization announced that following a review of existing epidemiological evidence, including new studies published since 2012, no changes to the Medical eligibility criteria for contraceptive use (MEC) recommendations for initiating or continuing hormonal contraceptives among women at high risk of HIV or living with HIV were warranted. Also, the revised guideline adds recommendations across classes of antiretroviral medications and the individual medications themselves.
In order to accelerate progress towards attainment of international development goals and targets in sexual and reproductive health, and in particular to contribute to meeting unmet need for contraceptive information and services, WHO has published guidance for policy-makers, programme managers providers and other stakeholders in the health sector on how to ensure that human rights are respected, protected and fulfilled, while services are scaled up to reduce unmet need for contraception
Postpartum family planning
Postpartum family planning is the prevention of unintended and closely spaced pregnancies through the first 12 months following childbirth. Providers, women, their families and communities, as well as policy-makers and programme managers, often do not think of the need for family planning at this time. They may not be aware that a woman’s fertility can return in the early months after birth and that with timely initiation most contraceptive methods are safe for the breastfeeding mother. Providing contraception during this period is both cost-effective for health systems (as couples are generally already visiting the health facility) and for clients who avoid unnecessary return trips to the health-care facility.
WHO convened a series of technical consultations between 13 and 16 May 2013 in order to plan the updates of its evidence-based family planning guidelines. As part of the process for updating these guidelines, WHO will be considering the evidence related to VTE risk associated with oral contraceptive formulations with various progestogens. Once this process has been completed, WHO will be in a position to provide global guidance on this issue